Sierra Summit Advisors LLC Acquires New Holdings in Medpace Holdings, Inc. $MEDP

Sierra Summit Advisors LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,637 shares of the company’s stock, valued at approximately $919,000.

Several other hedge funds also recently bought and sold shares of MEDP. Optiver Holding B.V. purchased a new position in Medpace during the third quarter valued at approximately $27,000. Geneos Wealth Management Inc. grew its stake in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. purchased a new position in Medpace during the fourth quarter valued at approximately $30,000. Elyxium Wealth LLC purchased a new position in Medpace during the fourth quarter valued at approximately $30,000. Finally, Quarry LP purchased a new position in Medpace during the third quarter valued at approximately $35,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This represents a 67.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of several recent analyst reports. Robert W. Baird reduced their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their price objective for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research note on Friday, February 13th. BMO Capital Markets reduced their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Finally, Leerink Partners cut their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $467.08.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, The Gross Law Firm, and Bleichmar Fonti & Auld, announced or promoted class action claims against Medpace Holdings, Inc. (MEDP), keeping legal overhang in focus for shareholders. Article Title
• Negative Sentiment: The lawsuits allege investor harm tied to disclosures about cancellation rates and other operating metrics, which could raise litigation costs and uncertainty around management credibility. Article Title
• Negative Sentiment: The repeated reminders about June 2026 filing deadlines suggest the legal situation is still active and could remain a drag on sentiment in the near term. Article Title
• Neutral Sentiment: Separately, Medpace shareholders approved governance changes enhancing voting rights at the company’s annual meeting, but this appears less immediately impactful than the litigation headlines. Article Title

Medpace Stock Performance

Shares of Medpace stock opened at $421.87 on Thursday. Medpace Holdings, Inc. has a 52-week low of $287.17 and a 52-week high of $628.92. The stock has a market capitalization of $12.05 billion, a price-to-earnings ratio of 26.52, a price-to-earnings-growth ratio of 2.13 and a beta of 1.19. The company has a fifty day moving average of $460.55 and a 200-day moving average of $521.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the prior year, the company earned $3.67 EPS. The firm’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.